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Abstract
The role an individual’s genetic background plays on phenotype and biological behavior of sporadic tumors remains
incompletely understood. We showed previously that lymphomas from Golden Retrievers harbor defined, recurrent
chromosomal aberrations that occur less frequently in lymphomas from other dog breeds, suggesting spontaneous canine
tumors provide suitable models to define how heritable traits influence cancer genotypes. Here, we report a
complementary approach using gene expression profiling in a naturally occurring endothelial sarcoma of dogs
(hemangiosarcoma). Naturally occurring hemangiosarcomas of Golden Retrievers clustered separately from those of non-
Golden Retrievers, with contributions from transcription factors, survival factors, and from pro-inflammatory and angiogenic
genes, and which were exclusively present in hemangiosarcoma and not in other tumors or normal cells (i.e., they were not
due simply to variation in these genes among breeds). Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) was among
genes preferentially enriched within known pathways derived from gene set enrichment analysis when characterizing
tumors from Golden Retrievers versus other breeds. Heightened VEGFR1 expression in these tumors also was apparent at
the protein level and targeted inhibition of VEGFR1 increased proliferation of hemangiosarcoma cells derived from tumors
of Golden Retrievers, but not from other breeds. Our results suggest heritable factors mold gene expression phenotypes,
and consequently biological behavior in sporadic, naturally occurring tumors.
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Introduction
The role individual genetic backgrounds play on phenotypes
and biological behavior of sporadic tumors remains to be
determined in any species. Recent studies explored how race
and ethnicity might influence gene expression and in turn
contribute to disease susceptibility in humans, but few differences
have been found [1,2,3]. Dog breeds may provide a useful
surrogate for human ethnic groups. While dogs retain individual
(outbred) traits, the derivation and maintenance of unique breeds
has led to restricted gene pools. These restricted gene pools can be
used to study heritable contributions to cancer susceptibility in
animals that develop tumors spontaneously and share the human
environment, but with the benefit of less ‘‘noise’’ from other
phenotypic variation.
Recent work has emphasized the utility of spontaneous canine
tumors as a robust, non-redundant model that complements
studies in humans and laboratory animals to understand cancer
genetics [4,5]. For example, the degree of medical surveillance in
dogs is second only to that in humans [6]; diseases such as cancer,
where traits are genetically complex and whose prevalence
increases with inbreeding, are well documented in dogs [5,6];
and dog populations are structured into .400 partially inbred
isolates (breeds) and a heterogeneous population of mixed-breed
dogs. Gene flow between breeds is restricted by pedigree barriers
and dogs of different breeds are often more (or less) susceptible to
different diseases [5].
Equally important, the canine genome closely resembles the
human genome, pet dogs share the human environment, and the
lifetime cancer risk in dogs and humans is similar [7,8]. Indeed,
some cancers appear to occur more frequently in dogs and the
incidence of many cancers varies according to breed, providing
opportunities to study tumors that are difficult to replicate in
humans or in inducible rodent models. Although cancer rates and
incidence in dogs have not been established systematically in
prospective or longitudinal studies, reproducible findings from
retrospective analyses and breed health surveys provide reasonable
estimates. Sporadic, naturally occurring hemangiosarcoma is
relatively common in dogs (much more so than angiosarcoma in
people, [9] with an apparent predilection for certain breeds such
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5549as German Shepherd Dogs, Boxers, and Golden Retrievers
[9,10,11,12,13,14]. The association between breed and disease is
strengthened by information from recent breed health surveys. For
example, cancer is the apparent cause of death for more than 60%
of Golden Retrievers in the U.S. and the lifetime risks for any
cancer, for hemangiosarcoma, and for non-Hodgkin lymphoma in
this breed are 1 in 2, 1 in 5, and 1 in 8, respectively [15]. In
contrast, the lifetime risk for any cancer and for hemangiosarcoma
in Irish Setters are estimated at 1 in 3 and 1 in 34, respectively
[16]. Other breed health surveys suggest hemangiosarcoma also is
common in Portuguese Water Dogs and Australian Shepherds,
whereas it is diagnosed less frequently in English Cocker Spaniels,
Rottweilers, Gordon Setters, and Vizslas, among others.
Given the strong association between breed and risk, we
predicted that gene expression profiles in tumors such as
hemangiosarcoma also would reflect features uniquely associated
with the breed. Furthermore, we anticipated that breed-related
gene expression profiles would uncover biologically and therapeu-
tically significant pathways that would inform etiology and identify
therapeutic targets. Specifically, the central hypothesis was that
naturally occurring hemangiosarcomas of Golden Retrievers
would be distinguishable from histologically similar hemangiosar-
comas of dogs from other breeds (non-Golden Retrievers) based
on the overexpression or underexpression of genes preferentially
concentrated in one or a few metabolic pathways, thus providing
insights into the pathogenesis of this disease. To test this
hypothesis, we used gene expression arrays and gene set
enrichment analysis (GSEA) to identify genes that vary according
to breed, as a proxy for heritability, in naturally occurring canine
hemangiosarcoma. We hypothesized this would outline the
potential influence of genetic background on cancer susceptibility
and progression in a more unique way than simply comparing
cancer cells to normal cells. For the first time, our data uncover
unique gene sets that are peculiar to hemangiosarcoma tumors
from a single dog breed (sharing a common genetic background).
Overall, this study emphasizes the potential benefits of gene
expression analysis and bioinformatics to study different biological
aspects unique to a cancer susceptible dog breed and can fill gaps
in our knowledge of disease susceptibility, heritability and
progression.
Results
Gene Expression Analysis Segregates Canine
Hemangiosarcoma According to Breed
While many human cancer cells have been shown to harbor
different gene expression signatures compared to their normal
counterpart cells (e.g., [17]), little has been done to define gene
expression profiles in canine tumors [18]. What is more, nothing
has been done to outline how these phenotypes are influenced by
heritable factors in any species. We showed elsewhere that
hemangiosarcoma cells separate from non-malignant splenic
hematoma cells based on gene expression profiles (Tamburini et
al, manuscript in preparation). In this analysis, unsupervised
clustering separated two major groups of hemangiosarcoma
samples, consisting of tumors from Golden Retrievers and tumors
from non-Golden Retrievers (GSE15086). Before we addressed
potential differences in these two groups, however, we sought to
ensure there were no hidden biases in the sample population.
During the course of our study, we received blood samples from 76
dogs with pathologically confirmed hemangiosarcoma, including
48 Golden Retrievers and 28 non-Golden Retrievers. There were
no differences between dogs in these two groups when comparing
age at diagnosis (mean6S.D.=9.362.6 and 8.662.6 years,
respectively), gender (male vs. female, intact or neutered), location
of the primary tumor, number of dogs treated, or outcome. The
characteristics of the population were similar to those previously
described both for Golden Retrievers [15] and for all dogs
independent of breed [14,19].
Our gene profiling experiments included every sample for
which viable tumor tissue was available to establish at least short-
term cell cultures (N=10, Table 1). The mean ages of the Golden
Retrievers (N=6) and non-Golden Retrievers (N=3) in this
subgroup were 10 and 8.3 years, respectively, while the latter
group consisted only of male dogs. The final sample originated
from a 9 year-old male Golden Retriever6Great Pyrenees F1 dog
(F1). Age and gender as variables did not account for the observed
clustering of the samples: when we segregated the 10 tumor
samples into groups where affected dogs were younger than 7
years vs. older than 7 years or into male vs. female dogs, there
were no significant differences in gene expression profiles.
Nevertheless, a pattern remained when the nine tumor samples
from purebred dogs (excluding the sample from the F1) separated
according to breed. False Discovery Rate (FDR) analysis separated
Golden Retriever and non-Golden Retriever samples into distinct
groups with a 5-gene signature of MHC DLA88, Forkhead box
protein F1, Thrombospondin-3 precursor, zinc finger protein
322A, and NAD(P) dependent steroid dehydrogenase. We
Table 1. Signalment (Demographics) of Dogs in Study.
Sample ID Diagnosis Breed Sex Age
CHAD G4 Hemangiosarcoma Golden Retriever Male 10
CHAD G6 Hemangiosarcoma Golden Retriever Female 12
CHAD G8 Hemangiosarcoma Golden Retriever Male 12
FROG Hemangiosarcoma Golden Retriever Female 10
JOURNEY Hemangiosarcoma Golden Retriever Female 11
TUCKER Hemangiosarcoma Golden Retriever Male 6
JOEY Hemangiosarcoma Rottweiler Male 9
DD-1 Hemangiosarcoma Golden Retriever6Great
Pyrenees
Male 9
CHAD P9 Hemangiosarcoma Portuguese Water Dog Male 9
DAL-4 Hemangiosarcoma Dalmatian Male 7
FOREST Unaffected Golden Retriever Male 10
HANK Unaffected Golden Retriever Male 10
TUX Unaffected Golden Retriever Male 10
JASPER Unaffected Boxer Male 8
T Unaffected German Shorthair Pointer Male 11
INGO Unaffected Rottweiler Male 10
QUANTUM Melanoma Golden Retriever Male 13
CHESTER Melanoma Golden Retriever Male 14
REP Melanoma Miniature Schnauzer Male 11
BAXTER L Osteosarcoma Golden Retriever Male 8
JAZZ Osteosarcoma Golden Retriever Male 7
KODIAK Osteosarcoma Great Pyrenees Male 9
STRETCH Osteosarcoma Greyhound Male 8.5
NELLIE T-cell lymphoma Golden Retriever Female 6
PUEBLO T-cell lymphoma Golden Retriever Male 11
MURPHY T-cell lymphoma Boxer Male 9
RUFFIAN B-cell lymphoma Boykin Spaniel Male 11
doi:10.1371/journal.pone.0005549.t001
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of different breeds would be subtle, thus the relatively small
number of genes was not surprising given the relatively low
expected discovery rate for this sample size. We took advantage of
the predicted true positive rate and identified additional genes that
were significantly different between the two groups at p,0.001.
Figure 1A is a heat map illustrating hierarchical clusters defined by
12 known genes, 4 unknown genes and 1 repeated gene (acid
ceramidase) isolated by two different probes. The list of known
genes includes an additional MHC gene, genes involved in DNA
replication and maintenance, and genes that regulate cellular
metabolism (Table 2). When gene differences were plotted
according to their cytogenetic location, there were few notable
changes. Unlike the significant global underexpression seen when
tumors were compared to non-malignant cells, samples from
Golden Retrievers showed a net increase in the sum of expression
of genes located in CFA 3, CFA 25 and CFA 30, and a net
reduction in the sum of expression of genes located in CFA 12,
CFA 14, CFA 29, CFA 32, CFA 33, and CFA 34. Predictably,
since samples from Golden Retrievers included 3 females, this
group also showed a net increase in the sum of expression of genes
in the X chromosome. Figure 1B shows the location of individual
genes that were recurrently and significantly overexpressed or
underexpressed in the Golden Retriever samples.
We used reverse transcriptase PCR followed by quantitative real
time PCR analysis of DLA-88 (MHC), TSP-3 and SMARCA-1
(SWI/SNF) expression to verify the microarray data (Figure 1C).
We included each of the non-Golden Retrievers (Dal-4, Joey, and
CHAD-P9) and three Golden Retrievers (CHAD G6, CHAD G4,
and Frog) for this analysis. The genes were chosen because they
may define MHC haplotypes or because of their relevance to
tumor biology; i.e., DLA-88 is an MHC class I gene [20],
homologues of TSP-3 are known to regulate angiogenesis [21],
and the SWI/SNF related gene SMARCA-1 is an ATP dependent
Figure 1. Golden Retriever Hemangiosarcoma Cells Segregate from Non-Golden Retriever Hemangiosarcoma Cells via Their
Expression Profile. A. Hierarchical clustering of 6 Golden Retriever (GR) hemangiosarcoma samples versus 3 non-Golden Retriever (nGR)
hemangiosarcoma samples (GEO series record GSE15086). Increasing green intensity indicates increased gene expression, increasing red intensity
indicates decreased gene expression, and black indicates no change. Bars represent groups that cluster together. B. Gene differences between
Golden Retrievers (GR) and non-Golden Retrievers (nGR) were plotted according to their cytogenetic location along the 38 autosomes and the X
chromosome. Tick marks represent individual genes that show differential regulation, with the color intensity (green to black to red) representing
expression changes as described in part A. Genes plotted received a p-value,0.05 and were derived from ANOVA analysis of the global list of filtered
genes. C. Quantitative expression analysis of 3 genes found in panel A, TSP-3, DLA88 (MHC), and SMARCA1 (SWI/SNF) that were differentially
expressed between Golden Retrievers with hemangiosarcoma and other breeds with hemangiosarcoma. Samples were evaluated for gene expression
changes by RT-PCR followed by qPCR. One sample originating from a non Golden Retriever dog (Dal-4) was normalized to 1.0 and used as a
reference; gene expression is presented as fold change compared to the reference sample. The samples used for real time PCR analysis (in the order
presented) include CHAD P9, Dal-4, Joey, DD1, CHAD G6, CHAD G4, and Frog. D. Schematic representation of gene expression changes between
Golden Retrievers and non Golden Retrievers with hemangiosarcoma grouped by biological function using ONTO/express gene ontology program
(vortex.cs.wayne.edu/Projects.html).
doi:10.1371/journal.pone.0005549.g001
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DNA replication, and DNA repair that is abnormally expressed in
certain tumors [22]. Figure 1C and Table 2 show TSP-3 and
DLA-88 were consistently underexpressed, whereas SMARCA-1
was consistently overexpressed in hemangiosarcomas from Golden
Retrievers. This latter gene is encoded in the X chromosome, but
the data suggest this is not purely a female bias: SMARCA1
expression was actually highest in cells from CHAD G4, which
was a male dog (Figure 1C, middle dog in the Golden Retriever
group). Student’s T-test for equal variance was used to calculate p-
values as an indication of statistical significance (Table 2). The
availability of a sample originating from an F1 mix-breed dog with
fortuitously known parentage (Golden Retriever6Great Pyrenees)
allowed us to ask interesting, albeit anecdotal questions. Specif-
ically, was this dog more similar to Golden Retrievers, to non-
Golden Retrievers, or would it reflect a ‘‘mixture’’ of both? When
we included this sample in the hierarchical clustering, the features
that separated the two groups were less distinguishable. Only 7 of
the 17 signals on the hit list remained among the 35 genes with
lowest p-values (p,0.0123) and 11 of 17 were found in the top 200
(p,0.04). This suggested that ‘‘Golden Retriever’’ contributed,
but did not completely control the gene expression signature in this
F1 dog’s tumor. Figure 1C shows indeed, that expression of TSP-3
in the F1 (Golden Retriever mix) was similar to the Golden
Retriever group and expression of MHC DLA-88 was similar to
the non-Golden Retriever group. Thus, the expression of genes in
the tumor was predictably modulated by the dog’s Golden
Retriever and non-Golden Retriever background.
One possible explanation for why Golden Retrievers separate
from non-Golden Retrievers in this analysis is that hierarchical
clustering by breed reflected unique properties of genetic variants
within the breed, rather than a particular influence of breed on
tumor phenotypes. To our knowledge, there is no reported
association between breed and MHC haplotypes, so this was
unlikely. Nevertheless, we examined whether the association
between expression of TSP-3, DLA-88, or SMARCA-1 and breed
(Golden Retriever) would hold in non-hemangiosarcoma samples.
Samples analyzed included blood leukocytes from healthy Golden
Retrievers and non-Golden Retrievers, blood leukocytes from
Golden Retrievers and non-Golden Retrievers that did not have
hemangiosarcoma, but were diagnosed with another cancer
(melanoma, non-Hodgkin lymphoma, or osteosarcoma), and the
hemangiosarcoma cells from each affected dog (Table 3). In blood
samples from healthy dogs and dogs with other types of cancers,
expression of TSP-3, MHC DLA-88, or SWI/SNF (SMARCA1)
was not significantly different among groups. However, in
hemangiosarcoma samples from Golden Retrievers, the expression
of TSP-3 and DLA-88 was consistently lower, and the expression of
SMARCA1 was consistently higher than in non-Golden Retrievers
(p,0.03).One interestingobservation isthattherangeofexpression
Table 2. Gene Expression Analysis Separates Golden Retriever Hemangiosarcoma Tumors from Non-Golden Retriever
Hemangiosarcoma Tumors
1.
Gene title Chrom. Function Fold Change p-value
similar to N-acylsphingosine amidohydrolase (acid ceramidase) 1 16 Metabolic processing 1.79 3.6E-04
MHC class 1 DLA-88 12 Cell-cell interaction 2603.8 1.7E-08
similar to Thrombospondin-3 precursor 7 Cell-cell interaction 22.08 1.1E-04
similar to NAD(P) dependent steroid dehydrogenase-like 5 Cell-cell interaction 21.91 1.7E-04
MHC class 1 DLA-64 12 Cell-cell interaction 22.81 6.9E-04
similar to Wiskott-Aldrich syndrome gene-like protein 14 Cell-cell interaction 21.60 7.4E-04
similar to staufen, RNA binding protein, homolog2 isoform LL (A) 29 Cell-cell interaction 22.02 8.2E-04
MHC class 1 DLA-88 12 Survival/apoptosis 2603.8 1.7E-08
similar to interferon stimulated exonuclease gene 29 kDa-like 1 3 Survival/apoptosis 22.23 5.1E-04
MHC class 1 DLA-64 12 Surivival/apoptosis 22.81 6.9E-04
similar to SWI/SNF-related matrix associated actin-dependent regulator of
chromatin remodeling
X Signaling/cell cycle 3.42 5.7E-04
similar to Structural maintenance of chromosomes4-like 1 protein 34 Signaling/cell cycle 1.72 6.8E-04
similar to Forkhead box protein F1 5 Transcription 21.65 9.3E-05
similar to zinc finger protein 322A 35 Transcription 21.68 1.5E-04
similar to SWI/SNF-related matrix associated actin-dependent regulator of
chromatin remodeling
X Transcription 3.42 5.7E-04
MHC class 1 DLA-88 12 Immune response 2603.8 1.7E-08
similar to interferon stimulated exonuclease gene 29 kDa-like 1 3 Immune response 22.23 5.1E-04
MHC class 1 DLA-64 12 Immune response 22.81 6.9E-04
Transcribed locus [Cfa.6637.1.A1_at] 9 Unknown 26.10 5.3E-04
Transcribed locus [Cfa.14890.1.A1_at] 28 Unknown 2.82 9.8E-04
— [CfaAffx.1401.1.S1_at] 1 Unknown 21.59 8.4E-04
— [Cfa.11358.1.A1_at] 16 Unknown 2.02 1.0E-03
1The list represents genes that were significant to p,0.001 comparing tumors from Golden Retriever to tumors from non-Golden Retriever. Each gene is grouped into
functional categories as defined in Fig. 1D. Mean fold change reflects the average expression in cells from Golden Retriever tumors over the average expression in cells
from tumors of non-Golden Retrievers; p-values were calculated after verifying the data were normally distributed using Student’s T-test. Some genes are found within
multiple functional categories.
doi:10.1371/journal.pone.0005549.t002
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samples from healthy dogs were narrow, but they were relatively
wide in blood samples from dogs that had non-hemangiosarcoma
tumors. Even so, the trends for expression of TSP-3 and DLA-88
are reversed in these samples. This suggests the differences were not
dueto variantsinthebreed,andinstead were dueto theinfluenceof
genetic background (breed) itself on hemangiosarcoma phenotypes.
Another possibility was that this difference would be reflected only
on tumor samples, so we assessed whether these genes had
significantly different calls when comparing our hemangiosarcoma
Golden Retriever expression arrays to expression arrays from
lymphoma and leukemia (30 Golden Retrievers) and from
osteosarcoma (9 Golden Retrievers). The association between
hemangiosarcoma and overexpression of acid ceramidase was
reinforced in these analyses, but neither TSP-3, nor DLA-88, nor
SMARCA1 showed differential expression according to breed in
lymphoma and leukemia or in osteosarcoma, although those
samples also appear to have different and unique sets of genes
whose expression varies as a function of breed (T. Phang, K. Gavin,
A. Sarver, and J. Modiano, unpublished data).
Pathway Analysis Provides Insight into
Hemangiosarcoma Susceptibility and Heritability
When we compared tumors from Golden Retrievers against
tumors from non-Golden Retrievers with hemangiosarcoma, we
found differentially expressed genes in several functional categories
defined by ONTO/express (Figure 1D). The single largest
category where genes differed between the two groups was genes
involved in transcription. We then applied GSEA to improve the
definition of pathways that may be influenced by heritable traits
and identified 77 gene sets with FDR,0.05 (Table S1). GSEA is
designed to identify categories, families, or sets of genes where
there are potentially small but coordinated changes in gene
expression. In other words, the intent was to discover groups of
genes (annotated by pathway) that ‘‘move’’ as a group, but where
the separation of any individual gene in the group would not be,
by itself, necessarily statistically significant. The top gene sets
identified with FDR,0.001 and with normalized enrichment
scores (NES),2.1 are shown in Table 4. GSEA highlighted unique
differences between hemangiosarcomas segregated by breed: for
example, Flt-1/VEGFR1 was exclusively enriched in GSEA
pathways separated according to breed (Figure 2). The enrichment
of VEGFR1 in these cells was especially intriguing. Previous flow
cytometric and immunocytochemical analysis of hemangiosarco-
ma samples from Golden Retrievers and from non-Golden
Retrievers showed expression of levels of CD133, CD34, c-Kit,
CD45, CD146, and avß3-integrin [23,24] were equivalent. Yet,
immunologic analysis verified the GSEA data. Figure 3A shows
immunocytochemical staining and immunoblotting for VEGFR1
and VEGFR2 in cell lines derived from Golden Retrievers and





of TSP-3 GR vs nGR
(Mean [Range]) p-value
Average fold change




vs nGR (Mean [Range]) p-value
Hemangio-sarcoma (tumor) 0.47 [0.39–0.56] 0.025 0.16 [0.07–0.26] 0.029 3.18 [2.04–4.32] 0.028
Healthy (blood) 0.84 [0.52–1.16] 0.623 1.14 [0.98–1.30] 0.783 0.78 [0.40–1.15] 0.571
Tumors (blood) 3.95 [0.82–7.08] 0.558 6.93 [2.49–11.37] 0.279 22.60 [1.98–43.22] 0.174
1qPCR was performed on genes as described previously in Figure 1C. Presented is the average fold change and average fold range from at least 3 samples which were
individually normalized to 18s control gene. P-values were calculated using the Welch t-test for samples with unequal variance, or Student’s t-test for equal variance.
Only Golden Retriever hemangiosarcoma compared to Non-Golden Retriever hemangiosarcoma showed differences that were statistically significant in each of the 3
genes analyzed.
doi:10.1371/journal.pone.0005549.t003
Table 4. Gene Set Enrichment Analysis Predicts Pathways Involved in Inflammation, Cancer, and Hypoxia Are Important for Golden
Retrievers with Hemangiosarcoma
1.
Gene set Description ES NES FDR
TARTE_MATURE_PC Genes overexpressed in polyclonal plasmablastic cells 0.71 2.63 ,0.001
IDX_TSA_DN_CLUSTER3 Genes downregulated during differentiation of 3T3-L1 fibroblasts into adipocytes 0.82 2.40 ,0.001
CARIES_PULP_UP Genes upregulated in pulpal tissue from extracted cavities 0.73 2.26 ,0.001
HYPOXIA_REVIEW Genes known to be induced by hypoxia 0.67 2.26 ,0.001
RUTELLA_HEPATGFSNDCS_UP Genes upregulated by hepatocyte growth factor treatment 0.70 2.19 ,0.001
NAKAJIMA_MCS_UP Most increased transcripts in activated human and mouse mast cells 0.77 2.14 0.001
TPA_SENS_EARLY_DN Downregulated by TPA at two consecutive timepoints between 15 min–3 hrs in sensitive
HL-60 cells
0.69 2.13 0.001
1The filtered gene list from Golden Retrievers with hemangiosarcoma vs. non-Golden Retrievers with hemangiosarcoma were compared using the GSEA software. ES
(Enrichment Score) is a value that represents how well the gene set is enriched within the selected gene list. NES (normalized enrichment score) corrects the ES for
differences in gene set size and can be used to compare across gene sets. A high ES or NES indicates that gene set is highly enriched within our gene list. FDR
represents the probability that the NES for a gene set gives a false positive finding. The highest FDR shown here is 0.005 indicating that there is a 0.005% chance that
the gene set indicates a false positive finding. The lists shown are those gene sets with an NES higher than 2.10.
doi:10.1371/journal.pone.0005549.t004
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not been arrayed (Emma) was included as a means to provide
validation of the data. Immunocytochemical staining verified each
of the Golden Retriever-derived cell lines expressed VEGFR1.
The relative expression of this protein as determined by
immunoblotting was higher in Emma and Frog (Golden Retriever)
cell lines than it was in Joey and in Dal-4 (non-Golden Retriever)
cell lines, and conversely, the relative expression of VEGFR2 was
higher in Joey and Dal-4 than it was in Emma and Frog
(Figure 3B).
Finally, we examined if these expression patterns had functional
correlates. We hypothesized that hemangiosarcoma cell lines from
Golden Retrievers and from non-Golden Retrievers would show
differential sensitivity to small molecules that selectively inhibit
VEGFR1 and VEGFR2 kinase activity. We selected two
compounds, referred to as ‘‘Drug 1’’ and ‘‘Drug 3’’ for simplicity,
with distinct affinity for VEGFR1 and VEGFR2. Drug 1 is a
selective VEGFR2 inhibitor, and Drug 3 is a related small
molecule with similar affinity for VEGFR2 as Drug 1, but with
100-fold greater affinity for VEGFR1. Figure 3C illustrates a
representative experiment that shows the VEGFR inhibitors we
selected had the predicted effects to inhibit activation of each
receptor in Dal-4 cells (one of the cell lines that had detectable
VEGFR1 and VEGFR2), as determined by the steady state level
of activating tyrosine phosphorylation at the residues homologous
to human Tyr1213 in VEGFR1 and Tyr951 in VEGFR2. As
would be predicted from the data in Figures 3A and 3B, we
noticed some variation in the levels of phosphorylated VEGF
receptors in the cells, mostly related to the overall steady state
expression of these proteins. Figure 4 shows that Drug 1 did not
significantly affect any of the seven cell lines tested. In contrast, cell
lines derived from Golden Retrievers showed significantly greater
proliferation in the presence of Drug 3 (Veronica.Tucker.
Emma.Frog). These responses were dose dependent and peaked
at concentrations of 0.1 to 10 nM. Drug 2, which has lower
affinity for both receptors, did not significantly alter proliferation
of hemangiosarcoma cells, but it is compelling that there was a
trend for greater proliferation by the Golden Retriever tumor lines
Figure 2. Gene Set Enrichment Analysis Validates the Hypothesis that the Golden Retriever Hemangiosarcoma Gene Set Is Involved
in Hypoxia, Inflammation, and Cancer. A. Bar graph representing the number of gene sets/pathways from the GSEA archived database that
were enriched in hemangiosarcoma samples from Golden Retrievers versus hemangiosarcoma samples from non-Golden Retrievers. Each gene on
the x-axis was present in the number of GSEA gene sets indicated on the y-axis (of 77 where FDR,0.05). B. Graphical representation of genes (x-axis)
present in each GSEA pathway/gene set (y-axis), where a filled box means the gene was present and enriched in that GSEA pathway. Increasing red
intensity reflects higher enrichment scores. The genes enriched in the highest number of gene sets are identified by name.
doi:10.1371/journal.pone.0005549.g002
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5549Figure 3. Expression of VEGF Receptors in Hemangiosarcoma Cells of Golden Retrievers and Non-Golden Retrievers. A.
Hemangiosarcoma cells from 4 Golden Retrievers (in order from top to bottom, Frog, Veronica, Tucker, Emma) and from 2 non-Golden Retrievers (Dal-
4 and Joey) were cultured in chamber slides and stained with antibodies against VEGFR1 and VEGFR2 as described in the methods. Staining was
visualized using epifluorescence. Bar=20 mm. B. Emma, Frog, Joey, and Dal-4 cells obtained during the log growth phase were used to quantify
expression of VEGFR1, VEGFR2 and ß-actin by immunoblotting. Conditions were optimized for linearity. Densitometric band quantification was done
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did not appear over-represented in any of the other tumor types
we examined from Golden Retrievers suggesting these changes are
specific to Golden Retrievers with hemangiosarcoma. Together,
the data indicate that gene expression patterns identified by gene
set enrichment analysis across distinct subgroups are biologically
significant, and in this case, they suggest VEGFR1 is not a decoy
receptor, but rather it is an active growth inhibitor in
hemangiosarcoma cells derived from Golden Retrievers.
Discussion
The relevance of naturally occurring canine tumors to improve
our understanding of cancer biology and genetics has been
increasingly recognized in recent years [4,5,25]. Canine tumors
can be utilized as a system to understand how genetic background
can influence the susceptibility of an individual to non-inherited
cancers. Due to the homogeneity among dog breeds, we can study
frequently occurring cancers within groups in a way that would be
difficult within the genetically diverse human population or in
laboratory animals, where most tumors are induced chemically or
by genetic manipulation.
We studied naturally occurring canine hemangiosarcoma to test
the hypothesis that patterns of gene expression could outline
biological differences between tumor cells originating from dogs of
a distinct breed that have a higher lifetime risk for hemangiosar-
coma. Hemangiosarcoma is ontogenetically related to human
angiosarcoma and Kaposi sarcoma, as all three are presumed to
arise from hemangioblastic or endothelial progenitors and they
share signaling abnormalities [19,23,26]. The highly metastatic
behavior and modest response to chemotherapy distinguish canine
hemangiosarcoma and human angiosarcoma from other common
soft tissue sarcomas that are locally invasive and generally
unresponsive to chemotherapy. We uncovered a set of hemangio-
sarcoma-associated genes peculiar to a single dog breed suggesting
these are modulated by (or with) heritable traits that may influence
risk for this cancer.
We considered carefully the choice of low passage cell lines vs.
intact tumors for these experiments. Tumors are in essence tissues
[27]. Tumor cells modify the microenvironment and are
themselves responsive to environmental cues. Nevertheless, to
understand the contribution of the tumor cells to biological and
pathological processes, it is important to be able to examine the
response on isolated cells. One approach to do this is
microdissection, but in a vascular tumor, it is difficult to
microdissect malignant tissue without retaining normal angiogenic
components, which are morphologically indistinguishable in many
cases, and blood elements. On the other hand, cell lines provide a
homogeneous, unlimited resource that can be extensively
characterized with regard to ontogeny. The potential limitations
of cell lines such as their restricted origin, possible in vitro evolution
or drift, and adaptation for growth in culture, can be mitigated by
use of controls that replicate culture conditions so that adaptation
to ex vivo growth is filtered from responsive transcript lists, and by
use of more than one sample. Our results show that despite the
different origin, isolation, and establishment of the cell lines we
used for these experiments, hemangiosarcomas retained unique
characteristics that distinguished them from other cultured (or
primary) cells, and that the recurrent finding of genes that are
over- or under-expressed in the samples is significant and
represents differences that can be traced to the developmental
process of the sample (ontogeny or pathological progression),
rather than to selection in culture. Ongoing experiments are
designed to define the correlation of these findings in intact tumor
samples where extracellular matrix associations are maintained.
Among genes whose expression differed between Golden
Retrievers and non-Golden Retrievers, a disproportionately high
number of genes encode transcription factors. This suggests that
transcriptional regulation might play a key role in disease
susceptibility and progression. Upregulation of SMARCA1 in
Golden Retrievers with hemangiosarcoma was intriguing since
changes in expression of a single transcriptional regulator can
create genome-wide disruption of a variety of genes, possibly
resulting in faster progression of the disease. It is thus feasible that
deregulation of SMARCA1 potentiates susceptibility and/or
heritability of hemangiosarcoma in Golden Retrievers. The
downregulation of MHC class I genes in hemangiosarcoma from
Golden Retrievers added a level of confidence, as these genes
represent the likely targets to define individual or breed-specific
differences. Preliminary assessment of MHC class I expression by
flow cytometry generally support the gene expression data, with
Frog (Golden Retriever) cells having no detectable MHC class I,
and Dal-4 (non-Golden Retriever) cells expressing MHC class I
molecules. This pattern is rather unique to hemangiosarcoma, as
Figure 4. Differential Sensitivity of Canine Hemangiosarcoma
Cell Lines to VEGFR Inhibitors. The effect of three VEGFR inhibitors
on proliferation and viability of hemangiosarcoma cells was tested in
vitro. The selectivity and half maximal inhibitory concentrations for
Drugs 1, 2, and 3 are listed in the Materials and Methods. Cells (10,000/
well) were plated in duplicate in a 96-well microtiter plates and allowed
to attach for 16 hr prior to addition of inhibitors at the indicated
concentration. Cells were then cultured for 72 hr, and the number of
viable cells was determined using the MTS assay. Absorption at 490 nm
for each well was averaged, and data normalized to % viability where
the mean of wells that received no treatment (0 nm) was consid-
ered=100%. The mean of two independent experiments is shown at
drug concentrations of 100 nM. P-values were calculated using
Student’s T-test.
doi:10.1371/journal.pone.0005549.g004
using Image J 1.37. Data are normalized to ß-actin using the sample with the highest expression for each receptor as the calibrator. C. Dal-4 cells were
cultured in complete media supplemented with VEGF (+), in the absence of serum and growth supplements (2), with or without Drug 3 (100 nM) or
Drug 1 (1 mM) as indicated. The activation status of VEGFR1 and VEGFR2 was examined using modification-state (phosphospecific) antibodies
directed against pVEGFR1-Tyr915 and pVEGFR2-Tyr875. ß-actin was used as a loading control, and HUVEC lysates were used as a specificity control for
VEGFR1.
doi:10.1371/journal.pone.0005549.g003
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(for example, leukemias) show robust expression of MHC class I.
The organization and control of genes in the canine MHC class I
locus remains poorly understood, and our data will undoubtedly
spur further study of how genetic variants within breed and
transforming factors might influence MHC class I expression. In
fact, breed-related polymorphisms or changes in expression level
have not been identified in normal canine somatic cells; thus,
downregulation of MHC class I genes (at least MHC DLA-88 and
DLA-64) in hemangiosarcoma cells from Golden Retrievers might
reflect selective pressure to evade immune responses, or perhaps a
response to autocrine or paracrine factors such as interferons or
other inflammatory mediators. This illustrates the potential benefit
of studies in dogs where a suitable experimental design could help
distinguish whether T-cell-mediated therapies that elicit produc-
tive responses in non-Golden Retrievers might be less successful in
Golden Retrievers [28], and similarly whether tumors of Golden
Retrievers provide suitable targets for natural killer cell-mediated
immunotherapy.
The specificity of these findings to one breed and one disease
were further illustrated when we compared Golden Retrievers
with hemangiosarcoma to Golden Retrievers with osteosarcoma
and non-Hodgkin lymphoma. In this case, we found acid
ceramidase was overexpressed in hemangiosarcomas, but not
osteosarcoma or non-Hodgkin lymphoma. Acid ceramidase
belongs to a family of anti-apoptotic genes that promote ceramide
production. At least one inhibitor of acid ceramidases, B13,
increased ceramide content selectively in tumor cells, inducing
apoptosis [29], suggesting acid ceramidase inhibitors may hold
therapeutic potential. It is thus possible that overexpression of this
gene is a consequence of interaction among factors that underlie
the observed predisposition of Golden Retrievers to hemangio-
sarcoma.
Another gene that was underexpressed in Golden Retrievers
with hemangiosarcoma compared to non-Golden Retrievers is
TSP-3, a member of the Thrombospondin family. A different
member of this family, TSP-1, has potent anti-angiogenic activity
[21] and has been a template for mimetics designed to treat cancer
[21,30]. Two of these mimetics, ABT-510 and ABT-526, have
yielded promising results in pet dogs with a variety of tumors,
albeit they were ineffective in dogs with hemangiosarcoma [31].
TSP-3 and TSP-1 are both calcium-binding proteins, but the
physiological role of TSP-3 is unknown [32,33]. The downregu-
lation of TSP-3 should be explored further in light of these clinical
results.
Despite these differences, the precise cause for increased risk to
develop hemangiosarcoma in Golden Retrievers remains unclear.
At least part of this perceived ‘‘risk’’ may be due to more rapid
disease progression. In other words, it is possible that transforma-
tion of hemangiosarcoma-initiating cells does not occur with
significantly greater frequency in Golden Retriever, but once it
occurs, progression to clinical disease is faster, thus leading to a
higher frequency of hemangiosarcoma diagnoses in Golden
Retriever. An interesting correlation along these lines was the
enrichment of VEGFR1 in tumors from Golden Retrievers, which
generally seemed to occur at the expense of VEGFR2. It is
important to note that the enrichment of VEGFR1 in tumors from
Golden Retrievers was not absolute, but rather occurred in
concert with various other genes that were preferentially expressed
in a coordinated fashion in these cells. We tested the possibility
that the ‘‘Golden Retriever background’’ might create a
phenotype that was responsive to VEGFR1. It seemed reasonable
to assume that growth of hemangiosarcoma cells, which are
presumed to be of endothelial origin, was driven by VEGF. In fact,
hemangiosarcoma cells make their own VEGF [23], resulting in
systemic elevation of this cytokine in affected dogs [34]. The
prevailing dogma states that VEGFR2 activates biochemical
cascades that result in proliferation and prevent programmed cell
death [35], whereas the action of VEGFR1 is less clear. VEGFR1
may transmit bona fide growth signals [36,37], or it may oppose
VEGFR2 signals directly or act as a decoy receptor [37,38]. In
some cases, VEGFR1 may even promote tumor growth and
metastasis [36]. Our data reveal two important points. The first is
that inhibition of VEGFR2 has little if any effect on proliferation
of canine hemangiosarcoma cells in culture. While this may seem
surprising, it is consistent with previous results in other
hemangiosarcoma cell lines [39] and suggests the VEGFR2
pathway may be an ontogenic relic in these cells. That is, VEGF
production and VEGFR2 expression may remain as part of the
differentiation program, but the cells are not ‘‘addicted’’ to, or rely
on, growth and survival signals transmitted through this
prototypical VEGF receptor. Instead, hemangiosarcoma cells rely
on other pathways for growth and survival. The second is that, at
least in hemangiosarcoma cells from Golden Retrievers that
express VEGFR1, this receptor may be more than simply a
‘‘decoy’’, and instead, signals transmitted by VEGFR1 may
dampen proliferation and/or differentiation.
These observations also are consistent with our findings that,
unlike what is seen in some sporadic vascular tumors in humans,
mutations of VHL are absent or infrequent in hemangiosarcoma,
suggesting this disease entity may represent a distinct or specialized
subset of blood vessel forming cells. Yoder et al [40] recently
described a myeloid cell that is a major participant in blood vessel
formation. This cell is a ‘‘vascular mimic’’ that can express a
variety of cell surface proteins associated with endothelial
precursor cells (CD133, CD34, VEGFR2), but it also has proteins
that belie hematopoietic origin (CD45, CD14, CD115), has
phagocytic activity, and does not contribute to the capillary
endothelial layer in transplanted matrix. These findings suggest
that plasticity of adult hematopoietic and mesenchymal stem cells
is limited, and differentiation of myeloid progenitors into
endothelial cells reflects functional rather than ontogenetic
plasticity, raising the possibility that canine hemangiosarcoma is
in fact a myeloid sarcoma. In this context, the inhibitory effects of
VEGFR1 would be predictable, as they mirror functions of this
receptor as an inhibitor of differentiation in human and murine
dendritic cells. It is worth noting that enrichment for VEGFR1
and other genes may be causally related to the incidence and
biological behavior of hemangiosarcoma in Golden Retrievers, but
it just as likely could be an effect of other risk factors in the breed
that are upstream regulators of these pathways, as our data do not
distinguish between these possibilities. Nevertheless, we interpret
the reproducibility of the results as an indicator that these are not
simply epiphenomena.
In conclusion, our data show that gene expression profiles are
informative to identify differences in tumor progression that may
be influenced by heritable factors. As important, our results
indicate these differences must be interpreted carefully and in the
context of biological pathways. Specifically, gene expression
profiling suggests that inflammation and angiogenesis are two
general processes that may be sensitive to modulation by a dog’s
genetic background in hemangiosarcoma. Inflammation, defined
by enrichment of cytokines such as IL8, IL5, IL18, and several
molecules that mediate adhesion and cell-cell interactions, might
reflect the action of a single aberrantly regulated molecule (for
example, IL1). Angiogenesis, defined by preferential enrichment of
VEGFR1 in tumor cells from Golden Retrievers might reflect
engagement of unique growth (inhibitory) pathways. However,
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cells, so we must consider the possibility that the cell of origin
in hemangiosarcoma retains moderate or extensive plasticity
and the heritable influence is manifested based on the stage of
differentiation achieved by the tumor cells. We should bear in
mind, then, that part of the ‘‘susceptibility’’ for this disease
in Golden Retrievers could be due to different biological
behavior in the early stages of the disease, and also to different
sensitivity of intrinsic tumor surveillance and/or chemotherapy.
That is to say, upregulation of VEGFR1, downregulation of MHC
class I, and downregulation of TSP-3 may underscore important
differences that explain susceptibility, pathogenesis, and response
to therapy. An alternative interpretation is that, regardless of the
ontogeny of the tumor-initiating cell, the transformation events
responsible for hemangiosarcoma involve pathways that render
VEGF signals mostly inconsequential and other pathways
controlled at the level of transcriptional regulation (e.g.,b y
SMARCA1) and/or survival (e.g., acid ceramidase) are important
determinants of the breed-dependent phenotype. Overall, this
study emphasizes potential benefits of gene expression analysis and
bioinformatics to study sporadic disease, and highlights the unique
contribution that studies of naturally occurring cancer in man’s




Samples used to derive canine hemangiosarcoma cell lines from
10 pet dogs [19,23,24] are listed in Table 1. Only two of the dogs
whose samples were used for the microarray experiments (Frog
and Journey) were related within 5 generations, and they were
separated by 3 generations (Frog was Journey’s ‘‘great aunt’’),
reducing the likelihood of lineage bias. Cryopreserved cultured
cells from the earliest available passages were used for these
experiments. Peripheral blood samples collected from healthy dogs
or from dogs with cancer prior to the initiation of any therapy (at
the time of tumor biopsy) were used as controls. Non-
hemangiosarcoma diagnoses included non-Hodgkin lymphoma,
melanoma, and osteosarcoma. Blood samples were age and
sex-matched to reduce variation. Every sample used for this
study was obtained with owner consent through protocols
reviewed by appropriate Institutional Animal Care and Use
Committees. Samples from healthy pet dogs were obtained as part
of routine diagnostic or well-health procedures. Samples from pet
dogs with cancer were obtained by the attending veterinarian as
part of medically necessary (biopsy) procedures or at the time of
necropsy.
RNA Isolation
RNA was isolated from tumor cells preserved in liquid nitrogen
or from blood stored at 280uC using the RNAeasy Mini Kit
and QIAshredder (QIAGEN, Valencia, CA), or the Ribopure
Blood Kit (Ambion, Austin, TX), respectively. RNA concentration
was determined using NanoDrop ND-1000 UV-Vis spectro-
photometer (NanoDrop Technologies, Wilmington, DE) and
quality measured using a 2100 bioanalyzer (Agilent, Santa Clara,
CA).
qPCR
Purified RNA was made into cDNA using the 1
st Strand cDNA
Synthesis Kit for RT-PCR (Roche Applied Science, Indianapolis,
IN). Real-time PCR was used to quantify cDNA using an ABI7500
sequence detector and Taqman PCR Master Mix Protocol (ABI,
Foster City, CA). Each PCR was performed at 50uC for 2 min,
95uC for 10 min, and then 40 cycles of 95uC for 15 s and 60uC for
1 min per cycle. Primers and Taqman probes were designed using
ABI Primer Express software (ABI). Forward primers, reverse
primers, and Taqman probes (59 to 39 orientation) were: for DLA-
88 CACCATTGTCATCGTCAGCAT, AGCTCCAATCACCC-
CAGAGA, and CTGCTCTGGTTCTCCT, for SMARCA-1
ATTTTGTGCATTTCATGTCTTCATC, CCTCAGCACAAG-
CTTCAAAGG, and AATCCTCTCAGTCCTTG, and for TSP3
TGCGAGGAGGGCGTCTT, GAGATTGGACCAAATGATG-
TTTTCT, and TGTATTCTGCTTCTCCC. Each PCR was
done in triplicate and normalized to endogenous 18s gene using
Taqman Fast Reagent Starter Kit (ABI). The samples used for
real time PCR analysis (in the order presented) include CHAD-
P9, Dal-4, Joey, DD1, CHAD-G6, CHAD-G4, and Frog.
Sample Size Determination and Microarrays
Approximately 2.5 mg of RNA were labeled using the
Affymetrix labeling protocol (Affymetrix, Santa Clara, CA). The
cRNA samples were then hybridized to Canine_2 gene expression
chips as described [41]. There are no precise tests to develop
sample size estimates for gene expression profiling, so we
started with theoretical principles and then applied empirical
observations to support the sample size for these experiments a
priori. The Canine_2.0 gene expression chip contains ,43,000
annotated sequences derived from the 7.56canine genome [42].
These represent virtually every known gene and a complement
of expressed sequence tags that provide strong redundancy
for expression profiling. We next considered that False Dis-
covery Rate statistical analysis provided the best method to set
thresholds for significance of elevated or reduced gene expression
[43], but additional multivariate analyses and gene set enrichment
would add further value to the analysis. We anticipated the
data might not be normally distributed; so, non-parametric tests
might be needed. As there is no analytical estimate of the power
of the Kruskal-Wallis test after false discovery rate corrections,
an approximation is useful in the case of small sample sizes. We
can estimate the proportion of times when perfect rank separation
between conditions might occur by chance as 2N!N!/(2N)!.,
where N is the number of samples in each group [44]. Empirical
tools are also available to calculate sample sizes, such as the Power
Atlas (http://www.poweratlas.org, ref. [45]). Analysis of similar
types of datasets in PowerAtlas suggests the sample size used for
these experiments (N=6 and 3) should provide .80% power
(a=0.05) to identify true positives, although the power to identify
true negatives would be lower.
Analysis of Gene Expression Data
Affymetrix Canine_2 microarray chip data were normalized
and filtered; we used robust multiarray average (RMA) to obtain
mean values for the intensity of the probe pairs and define the
expression levels of the mRNA based on modeling perfect match
signal intensities and ignoring mismatch signal [46]. The
Canine_2 chip contains 42,900 genes; prior to statistical analysis,
data were preprocessed to filter control probe sets, genes with
‘‘absent’’ calls in all samples, and transcripts that did not vary
significantly from the median variance for the whole array. The
data discussed in this publication have been deposited in NCBI’s
Gene Expression Omnibus [47] and are accessible through GEO
Series accession number GSE15086 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE15086). After normalization
and filtering, 13,758 genes remained for a comparison of Golden
Retriever to non-Golden Retriever samples. There were 16 genes
that differed with a p-value,0.001 (not corrected for multiple
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multiple testing. The variation in expression for three of these was
verified by qPCR. Partek software (Partek Incorporated, St. Louis,
MO) was used to run analysis of variance (ANOVA) from the
filtered gene lists to corroborate the gene list. These genes were
ordered into hierarchical clusters using the Euclidean algorithm as
the distance measure, and the Average Linkage Clustering
algorithm as the linkage method, and into virtual karyotypes
based on their chromosomal assignment. ONTO/express (http://
vortex.cs.wayne.edu/ontoexpress/) was used to define biological
function of genes from each comparison, and Gene Set
Enrichment Analysis (GSEA, http://www.broad.mit.edu/gsea/)
[48] to examine how expression profiles from the filtered lists fit
into known and archived biological pathways.
Immunocytochemistry and Immunoblotting
Expression of the vascular endothelial growth factor (VEGF)
receptors Flk-1/VEGFR2 and Flt-1/VEGFR1 was examined
by immunocytochemistry and by immunoblotting [19,49,50].
These experiments included an additional cell line from a
Golden Retriever hemangiosarcoma (Emma) that was recently
developed and therefore not used for the array experiments,
but allowed us to validate gene set enrichment in an independent
sample. Briefly, for immunocytochemistry cells were grown in
dual chamber slides, fixed in acetone, air-dried, and stained
with antibodies against VEGFR1 (Santa Cruz Biotechnology,
Santa Cruz, CA) or VEGFR2 (Cell Signaling, Danvers, MA) using
a modified streptavidin-biotin complex method (IHC Services,
Smithville, TX). Control lysates from human umbilical vein
endothelial cells (HUVEC) were purchased from Santa Cruz
Biotechnology. Microscopic images were obtained using the
fluorescent properties of the Fast Red dye under ultraviolet
light as described [51]. Fluorescent images were acquired using
an Olympus IX71 inverted microscope with an Olympus
DP70 cooled digital camera (Leeds Precision Instruments, Golden
Valley, MN). Transmitted light images under phase contrast were
captured in automatic white balance mode. Fluorescent images
were captured in automatic black balance mode (exposure times of
1/1.5 sec). Brightness for the composite image only was optimized
using Adobe Photoshop CS3 (Adobe, San Jose, CA). For
immunoblotting, cells were cultured to log-growth phase,
dettached from plates using Accutase and extracted using
RIPA buffer as described [23,50]. Experiments to assess
phosphorylation of VEGFR1 and VEGFR2 were done in
cells cultured in complete media supplemented with serum and
VEGF, media depleted of serum and VEGF (0.5% serum with no
exogenous VEGF), or complete, supplemented media with
VEGFR inhibitors ‘‘Drug 1’’ and ‘‘Drug 3’’ (see below). Inhibitors
were used in experiments at a concentration range of 100 nM
to 1 mM, for 30 minutes to 18 hr. Cells were harvested as
described above in the presence of phosphatase inhibitors
(sodium fluoride, sodium orthovanadate) and excess phosphatase
substrates (sodium pyrophosphate and ß-glecrophosphate) as
described [52,53]. Modification state antibodies directed against
pVEGFR1-Tyr1213 and pVEGFR2-Tyr951 were obtained
from Calbiochem and Cell Signaling, and diluted for use
to 1:200 and 1:125, respectively. Brightness and contrast for
the immunoblot images were optimized using Adobe Photoshop
CS3. Non-adjoining lanes (HUVEC) are demarcated by a black
line.
Cell Culture and Proliferation
The hemangiosarcoma cell lines Frog, Tucker, Dal-4, Joey, and
DD-1 (Table 1) were cultured as described previously [23].
Veronica and Emma cell lines were developed as described [23]
from splenic and a metastatic brain hemangiosarcomas, respec-
tively, both from Golden Retrievers. For VEGFR inhibition, cells
were cultured in the presence of small molecules that selectively
inhibit VEGFR kinase (VEGF Receptor Tyrosine Kinase
Inhibitor II, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]-
benzamid, hereafter called ‘‘Drug 1’’; VEGFR Tyrosine Kinase
Inhibitor III, KRN633, N-(2-Chloro-4-((6,7-dimethoxy-4-quina-
zolinyl)oxy)phenyl)-N9-propylurea, hereafter called ‘‘Drug 2’’; or
VEGF Receptor Kinase Inhibitor IV, 3-(3-Thienyl)-6-(4-methox-
yphenyl)pyrazolo[1,5-a]pyrimidine, hereafter called ‘‘Drug 3’’).
The half maximal inhibitory concentrations for VEGFR1 and
VEGFR2 for Drugs 1, 2, and 3, respectively are 180 and 20, 170
and 160, and 1.9 and 19. Cells (10,000/well) were plated in
duplicate in 96-well microtiter plates and allowed to attach for
16 hr prior to addition of inhibitors over a concentration range
from 1 pM to 1 mM. Cells were then cultured for 72 hr, and the
number of viable cells was determined using the MTS assay
(Promega, Madison, WI). Absorption at 490 nm for each well was
averaged, and data normalized to % viability where the mean of
wells that received no treatment (0 nm) was considered=1. The
results show the means of two independent experiments for each
cell line.
Supporting Information
Table S1 Complete List of 77 Gene Sets Influenced by
Heritable Traits Identified Using GSEA with FDR#0.05
Found at: doi:10.1371/journal.pone.0005549.s001 (0.10 MB
DOC)
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